Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study.

Everts-Graber, J; Reichenbach, S; Gahl, B; Ziswiler, H R; Studer, U; Lehmann, T

Everts-Graber, J; Reichenbach, S; Gahl, B; Ziswiler, H R; Studer, U; Lehmann, T.

Afiliação

Everts-Graber J; OsteoRheuma Bern, Bahnhofplatz 1, Bern, Switzerland. Electronic address: judith.everts@hin.ch.
Reichenbach S; Department of Rheumatology, Immunology and Allergology, University Hospital, Bern, Switzerland; Institute for Social and Preventive Medicine, University of Bern, Switzerland.
Gahl B; Clinical Trial Unit (CTU) Bern, University of Bern, Switzerland.
Ziswiler HR; OsteoRheuma Bern, Bahnhofplatz 1, Bern, Switzerland.
Studer U; OsteoRheuma Bern, Bahnhofplatz 1, Bern, Switzerland.
Lehmann T; OsteoRheuma Bern, Bahnhofplatz 1, Bern, Switzerland.

Bone ; 144: 115830, 2021 03.

Article em En | MEDLINE | ID: mdl-33359006

Assuntos

Conservadores da Densidade Óssea; Osteoporose Pós-Menopausa; Densidade Óssea; Conservadores da Densidade Óssea/uso terapêutico; Denosumab/efeitos adversos; Feminino; Humanos; Estudos Retrospectivos; Fatores de Risco; Suspensão de Tratamento

Palavras-chave

Bisphosphonates; Denosumab; Discontinuation; Fracture; Osteoporosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Osteoporose Pós-Menopausa / Conservadores da Densidade Óssea Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Bone Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google